- Previous Close
5.99 - Open
6.05 - Bid 7.01 x 100
- Ask 7.06 x 400
- Day's Range
6.05 - 7.07 - 52 Week Range
5.71 - 11.72 - Volume
1,319,083 - Avg. Volume
438,521 - Market Cap (intraday)
383.914M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
26.07 - EPS (TTM)
0.27 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.63
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
www.voyagertherapeutics.comRecent News: VYGR
View More
Performance Overview: VYGR
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VYGR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VYGR
View MoreValuation Measures
Market Cap
383.91M
Enterprise Value
59.83M
Trailing P/E
26.07
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.52
Price/Book (mrq)
1.14
Enterprise Value/Revenue
0.42
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
6.28%
Return on Assets (ttm)
-1.11%
Return on Equity (ttm)
3.38%
Revenue (ttm)
143.77M
Net Income Avi to Common (ttm)
9.02M
Diluted EPS (ttm)
0.27
Balance Sheet and Cash Flow
Total Cash (mrq)
371.02M
Total Debt/Equity (mrq)
13.99%
Levered Free Cash Flow (ttm)
-506.5k
Research Analysis: VYGR
View MoreCompany Insights: VYGR
VYGR does not have Company Insights
Research Reports: VYGR
View MoreDaily – Vickers Top Buyers & Sellers for 10/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/02/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/27/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.